Effectiveness and safety of ixazomib–lenalidomide–dexamethasone in high-cytogenetic-risk relapsed/refractory multiple myeloma — results of the Polish Myeloma Group observational study
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI